Summit Therapeutics Inc [SMMT] stock is trading at $26.29, down -1.50%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SMMT shares have lost -6.94% over the last week, with a monthly amount glided 0.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on July 01, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $30. Previously, Leerink Partners started tracking the stock with Underperform rating on June 11, 2025, and set its price target to $12. On March 26, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $35 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Evercore ISI initiated its recommendation with a Outperform and recommended $30 as its price target on March 12, 2025. Goldman started tracking with a Buy rating for this stock on February 28, 2025, and assigned it a price target of $42. In a note dated January 08, 2025, Truist initiated a Buy rating and provided a target price of $35 on this stock.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $11.29 and $36.91 over the past year. Currently, Wall Street analysts expect the stock to reach $38.25 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $26.29 at the most recent close of the market. An investor can expect a potential return of 45.49% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.3, Equity is -2.09 and Total Capital is -0.72. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.50 points at the first support level, and at 24.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.91, and for the 2nd resistance point, it is at 27.52.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 5.13. Further, the Quick Ratio stands at 5.13, while the Cash Ratio is 4.94.
